Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study

被引:80
作者
Menson, Esse N.
Walker, A. Sarah [1 ]
Sharland, Mike
Wells, Carole
Tudor-Williams, Gareth
Riordan, F. Andrew I.
Lyall, E. G. Hermione
Gibb, Diana M.
机构
[1] MRC, Clin Trials Unit, London NW1 2DA, England
[2] St Georges Hosp NHS Trust, London SW17 0QT, England
[3] St Marys Hosp NHS Trust, London W2 1NY, England
[4] Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2006年 / 332卷 / 7551期
基金
英国医学研究理事会;
关键词
D O I
10.1136/bmj.332.7551.1183
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To measure the extent of underflosing of antiretroviral drugs in children. Design Multicentre cohort study. Setting Clinical centres in hospitals in the United Kingdom and Ireland in the collaborative HIV paediatric study (CHIPS). Participants 615 HIV infected children aged 2-12 years receiving antiretrovirals. Main outcome measures Doses relative to weight and height compared with current recommended doses in 2004 European guidelines. Results The CHIPS cohort of 934 children comprises 80% of diagnosed HIV infected children in the UK and Ireland between January 1997 and March 2005, of which 66% (615) aged 2-12 years were prescribed antiretrovirals. Actual doses standardised to weight or surface area varied widely across individual drugs, anfiretroviral class, and calendar time, with children underdosed (prescribed less than 90% of current recommended doses) from 6-62% child time at risk. Three serious issues in prescribing antiretrovirals, which may also be relevant to paediatric prescribing in general, were identified. Firstly, dosing was inadequate before incorrect recommendations at licensing were later revised when important pharmacokinetic results emerged. Secondly, guidelines stating dosage alternatives (by weight/surface area) for the same drug led to different and inconsistent doses. And, thirdly, ongoing growth was not adjusted for. Conclusions Largely inadvertently, HIV infected children in die United Kingdom and Ireland have been underdosed with antiretrovirals, 1-highlighting problems applicable throughout paediatric prescribing.
引用
收藏
页码:1183 / 1186
页数:8
相关论文
共 20 条
[1]   VERTICALLY TRANSMITTED HIV-INFECTION IN THE BRITISH-ISLES [J].
ADES, AE ;
DAVISON, CF ;
HOLLAND, FJ ;
GIBB, DM ;
HUDSON, CN ;
NICHOLL, A ;
GOLDBERG, D ;
PECKHAM, CS .
BRITISH MEDICAL JOURNAL, 1993, 306 (6888) :1296-1299
[2]  
ALEXANIAN A, 2005, 12 C RETR OPP INF BO
[3]   Clinical trials in children [J].
Caldwell, PHY ;
Murphy, SB ;
Butow, PN ;
Craig, JC .
LANCET, 2004, 364 (9436) :803-811
[4]  
COSTELLO I, 2005, BNF CHILDREN
[5]  
*FOOD DRUG ADM, 2006, PED DRUG DEV
[6]   Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children [J].
Gatti, G ;
Castelli-Gattinara, G ;
Cruciani, M ;
Bernardi, S ;
De Pascalis, CR ;
Pontali, E ;
Papa, L ;
Miletich, F ;
Bassetti, D .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (11) :1476-1482
[7]   Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland [J].
Gibb, DM ;
Duong, T ;
Tookey, PA ;
Sharland, M ;
Tudor-Williams, G ;
Novelli, V ;
Butler, K ;
Riordan, A ;
Farrelly, L ;
Masters, J ;
Peckham, CS ;
Dunn, DT .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7422) :1019-1023
[8]   Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1 [J].
Gortmaker, SL ;
Hughes, M ;
Cervia, J ;
Brady, M ;
Johnson, GM ;
Seage, GR ;
Song, LY ;
Dankner, WM ;
Oleske, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (21) :1522-1528
[9]   Clinical trials in children: Problems and pitfalls [J].
Kauffman R.E. .
Paediatric Drugs, 2000, 2 (6) :411-418
[10]   Antiretroviral pharmacokinetics in the paediatric population - A review [J].
King, JR ;
Kimberlin, DW ;
Aldrovandi, GM ;
Acosta, EP .
CLINICAL PHARMACOKINETICS, 2002, 41 (14) :1115-1133